Roche Holding AG (OTCMKTS:RHHBY) Receives Average Rating of “Hold” from Brokerages

Roche Holding AG (OTCMKTS:RHHBY) has earned a consensus recommendation of “Hold” from the six analysts that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company.

A number of equities analysts have recently commented on RHHBY shares. Sanford C. Bernstein upgraded Roche to a “strong-buy” rating in a report on Thursday, January 30th. Morgan Stanley initiated coverage on Roche in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company.

Institutional Trading of Roche

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bard Financial Services Inc. increased its position in shares of Roche by 156.8% during the third quarter. Bard Financial Services Inc. now owns 80,500 shares of the company’s stock worth $3,216,000 after acquiring an additional 49,150 shares during the period. Minot DeBlois Advisors LLC bought a new stake in Roche during the 4th quarter valued at $752,000. SVB Wealth LLC bought a new position in shares of Roche during the 4th quarter worth $555,000. Verity Asset Management Inc. purchased a new position in shares of Roche during the third quarter valued at $253,000. Finally, IHT Wealth Management LLC bought a new stake in shares of Roche in the third quarter valued at about $236,000.

Roche Trading Down 0.5 %

Shares of OTCMKTS:RHHBY opened at $40.85 on Wednesday. Roche has a 12 month low of $29.20 and a 12 month high of $42.43. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86. The company has a 50-day moving average price of $37.14 and a 200 day moving average price of $38.31.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.